December 25, 2017

Multiplex DX Was Listed in the New Europe 100: Eastern Europe’s Emerging Technology Star

The 2017 New Europe 100 is the fourth annual list of central and eastern Europe’s brightest and best citizens who are changing the region’s societies, politics or business environments and displaying fresh approaches to prevailing problems. The individuals from 14 countries were selected by Res Publica, the Warsaw-based journal; Google; the state-supported Visegrad Fund promoting integration within central Europe; and the Financial Times.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments: “We're very excited to be on this list! Our team worked really hard last year. We launched new products, entered TOP 100 Slovak innovative companies list, became an overall winner of the prestigious Startup Awards 2016. This is another sign for us that we are on the right track and will keep on moving with other biotech innovations next year!”

The aim of the New Europe 100 is to raise the profile of the changemakers in emerging Europe and to build connections among those in the vanguard. For more details of the list see

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News